SIDEROS Phase 3 Trial of Puldysa in Duchenne Patients Completes Enrollment

Print Friendly, PDF & Email

The SIDEROS Phase 3 clinical trial, investigating if oral Puldysa (idebenone) can be added to a stable glucocorticoid regimen to more effectively slow lung function decline in boys and men with Duchenne muscular dystrophy (DMD), has completed enrollment, Santhera Pharmaceuticals announced. A planned analysis demonstrated the study, while not […]